Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neoplasia
Main Authors: Oosterwijk-Wakka, Jeannette C., de Weijert, Mirjam C.A., Franssen, Gerben M., Leenders, William P.J., van der Laak, Jeroen A.W.M., Boerman, Otto C., Mulders, Peter F.A., Oosterwijk, Egbert
Format: Artigo
Jezik:Inglês
Izdano: Neoplasia Press 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4351300/
https://ncbi.nlm.nih.gov/pubmed/25748241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.12.011
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki